SCHEMBL15906238

SCHEMBL15906238

CC(C)(CBr)C(=O)N[C@H]1CC[C@H](C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.46
ALDH1A1 P00352 5/20 0.39
ADRA2A P08913 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PKM P14618 1/20 0.38
PDK1 Q15118 1/20 0.38
PDK2 Q15119 1/20 0.38
PDK3 Q15120 1/20 0.38
PDK4 Q16654 1/20 0.38
RAB9A P51151 5/20 0.37
NPC1 O15118 4/20 0.37
GAA P10253 2/20 0.36
SSTR4 P31391 2/20 0.36
SSTR1 P30872 1/20 0.36
TAS1R3 Q7RTX0 2/20 0.35
TAS1R1 Q7RTX1 2/20 0.35
TAS1R2 Q8TE23 2/20 0.35
POLB P06746 1/20 0.35
RECQL P46063 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15906245 0.84 EPHX1 (0.47) EPHX1ALDH1A1ADRA2ASMN1; SMN2PKM
SCHEMBL14655013 0.82 EPHX1 (0.46) EPHX1ALDH1A1ADRA2ASMN1; SMN2PKM
SCHEMBL14652133 0.81 PKM (0.39) EPHX1ALDH1A1PKMPDK1PDK2
SCHEMBL803835 0.81 EPHX1 (0.44) EPHX1ALDH1A1ADRA2ASMN1; SMN2PKM
SCHEMBL14654940 0.81 EPHX1 (0.44) EPHX1ALDH1A1ADRA2ASMN1; SMN2PKM
SCHEMBL15906218 0.79 EPHX1 (0.43) EPHX1ALDH1A1ADRA2ASMN1; SMN2PKM
SCHEMBL26140573 0.79 EPHX1 (0.53) EPHX1ALDH1A1ADRA2ASMN1; SMN2PKM
SCHEMBL13246733 0.79 EPHX1 (0.53) EPHX1ALDH1A1ADRA2ASMN1; SMN2PKM
SCHEMBL14654906 0.78 L3MBTL1 (0.36) EPHX1ALDH1A1PKMPDK1PDK2
Hydrochloric Acid SCHEMBL29904533 0.77 EPHX1 (0.52) EPHX1ALDH1A1ADRA2ASMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791257-B2 Substituted pyrrolotriazines as protein kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-07-29 US disclosed